Kamada Stock
Kamada Ltd.
Company data
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Country
- Israel
- CEO
- Amir London
- Employees
- 462
- Market cap
- $448 M
- IPO
- 31/05/2013
Kamada Ltd. is a biopharmaceutical firm focused on developing, manufacturing, and distributing protein therapeutics derived from human plasma. The company operates through two core business areas: its proprietary product segment and its distribution division. Its own manufactured portfolio includes KAMRAB/KEDRAB for…
Kamada stock: price history
1D
-0.9%
1W
-4.0%
1M
-5.3%
6M
-8.6%
YTD
+9.9%
1Y
+15.0%
2Y
+47.8%
5Y
+47.2%
10Y
+42.4%
Next earnings date
Next earnings date
09/11/2026 (in 23 days)
Volatility around earnings
~18% stronger price swings than usual
Kamada stock scores
- Valuation
Visible after free registration
- Trend
Visible after free registration
- Quality
Visible after free registration
- Dividend
Visible after free registration
- Growth
Visible after free registration
- Insider
Visible after free registration
- Earnings
Visible after free registration
- Revisions
Visible after free registration
- Sentiment
Visible after free registration
- Short Pressure
Visible after free registration
Register for free
Unlock all 11 scores
- 5 credits free on registration
- Access to virtual portfolios and watchlist
- No credit card, no payment details needed
- No subscription, no minimum term
- Our own servers in Germany, no US cloud
Deterministically calculated from financial metrics, not investment advice. Updated nightly, last on 06/10/2026.
Business model & megatrends
Robust business model that benefits noticeably from at least one megatrend.
Kamada Ltd. is a biopharmaceutical company focused on the development, manufacturing, and distribution of protein therapeutics derived from human plasma. The business model is divided into two segments: a proprietary segment for specialty products for the prevention and treatment of severe diseases, and a third-party product distribution segment. Marketing is conducted internationally through distributors and in the United States through strategic partners. Geographically, revenues are distributed across various regions, with significant shares in Latin America, Canada, and other foreign markets.
- Revenue model
- Transactional
- Recurring revenue
- High
- Pricing power
- Strong
- Moat
- Wide
- Moat type
- Efficient scale
- Capital intensity
- High
- Customer concentration
- Unknown
Ask the agents about Kamada
Analyst assessment of Kamada
PRICE TARGET LOW
US$15.00
CONSENSUS
US$15.00
MEDIAN
US$15.00
PRICE TARGET HIGH
US$15.00
0
STRONG BUY
5
BUY
1
HOLD
0
SELL
0
STRONG SELL
6
TOTAL · Buy
As of: 09/12/2025
Kamada stock metrics
P/E
20.26
P/B
1.67
EV/EBITDA
10.25
RETURN ON EQUITY
3.4%
NET MARGIN
16.9%
DEBT/EQUITY
0.04
DIVIDEND YIELD
5.4%
AS OF
30/06/2026
Free float & liquidity
FREE FLOAT
54.9%
FLOAT SHARES
31,655,997
AVG. DAILY VOLUME (30D)
117,018
Insider transactions (SEC)
Brenner Yael
Livneh Nir
Tsur David
Brenner Yael
Brenner Yael
Institutional holders
Dividends & Stock splits
Dividends
Stock splits
Comparable stocks
Frequently asked questions about Kamada stock
What does Kamada do?
Kamada Ltd. is a company in the Healthcare sector, Drug Manufacturers - Specialty & Generic industry, headquartered in Israel.
The CEO is Amir London, the company employs around 462 people.
The IPO was on 31/05/2013; the stock trades on NASDAQ under the ticker KMDA.
What do analysts say about Kamada stock?
6 analysts rate the stock, the consensus is Buy (as of 09/12/2025).
The average price target is US$15.00, ranging from US$15.00 to US$15.00, with a median of US$15.00.
This is an external assessment, not a statement by Market Jury.
When does Kamada report next?
The next earnings date is 09/11/2026.
Around past earnings, price swings were roughly 18% stronger than usual.
Does Kamada pay a dividend?
Yes. The last dividend was US$0.17 per share, ex-date 27/08/2026, paid on 17/09/2026.
The dividend yield is 5.4% (as of 30/06/2026).
Which stocks are comparable to Kamada?
Comparable stocks include Teva Pharmaceutical Industries, Merck, Takeda Pharmaceutical Company, Zoetis, Sandoz Group, Viatris, Lantheus Holdings and Amneal Pharmaceuticals.
How can I get Kamada stock analyzed?
Clicking "Analyze stock" lets five strategies assess Kamada against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.